Elderly, advanced, secondary recurrence of lung cancer patients do not give up the opportunity of surgery, still can be cured

2022-06-01 0 By

Magnolia bark ark team compiled | according to the world health organization’s international agency for research on cancer (IARC) released the latest data, 2.2 million, 2020 new cases of lung cancer deaths in 1.8 million cases, high morbidity and high mortality rate for lung cancer to become everyone to “refrain” “devil”.However, many lung cancer patients can be cured clinically if they can be removed surgically.Clinically, lung cancer is often divided into stage I-IV, CT examination found about 2cm mass is usually stage I-IB.It is generally believed that for non-invasive tumors < 2cm, if the solid component < 50%, the 10-year survival rate of patients can be ≥97%.If the solid component is more than 50%, and there are some solid nodules, or nipple, mucus and micronipple components appear on the pathological section, it indicates a high degree of malignancy, infiltration and metastasis may occur, and timely treatment should be given.If the pathologic findings of a pulmonary nodule show adherent growth, it is a very early, low-grade tumor.Currently, the NCCN or CSCO guidelines recommend a surgery-based multidisciplinary approach for early lung cancer.If it can be detected early and removed in time, patients with lung cancer will have a good prognosis.In addition, the emergence of thoracoscopic surgery and Da Vinci robot surgery not only further improves the therapeutic effect of lung cancer, but also reduces the complications caused by surgery, laying a foundation for improving the prognosis effect of lung cancer patients.A 2020 study showed that patients with lung cancer who underwent thoracoscopic surgery had a higher survival rate (50.5% vs 48.4%), a higher relapse-free survival rate (60.5% vs 44.6%), and a shorter hospital stay compared with thoracotomy [3].Results of the study, published in the Journal of Thoracic Disease in July 2020, showed that compared with immature Robotic Da Vinci surgery and thoracoscopic surgery,Mature Da Vinci robotic surgical technology can significantly reduce the postoperative complication rate of lung cancer patients (15.2% vs 34.9% vs 39.1%) and shorten the length of hospital stay of patients (2 vs 3 vs 4 days) [4].Previously, Hopu Fangzhou's client, Ms. Li, a patient with in-situ lung cancer, was successfully removed with the help of Kenji Suzuki, director of respiratory Surgery department of Sunheaven Hospital affiliated to Sunheaven University in Japan, and had no recurrence for six years after surgery.Suzuki pointed out that the removal of lung cancer in situ would not have any effect on Li's life expectancy.Recommended reading: Increased tumor markers, suspected recurrence of in-situ lung cancer, a remote consultation reassured her 2.Older people, especially those over 75, are at higher risk of developing lung cancer, according to an analysis of survey data.However, for any patient with early tumor, regardless of age, it is necessary to fully evaluate the risk of surgery and determine whether to use surgical resection.Surgical resection of Lung Cancer in patients over 80 years of age significantly improves quality of life, according to a study published in The June 2021 issue of Clinical Lung Cancer.Therefore, age should not be a contraindication for surgery, even for lung cancer patients over 80 years old can be surgically removed to improve the prognosis.[6]3. Patients with locally advanced lung cancer still have the possibility of surgery, if there is no distant metastasis, there is still a chance of clinical cure by surgical resection.On the other hand, the emergence of neoadjuvant therapy can also help lung cancer patients shrink their tumors, and even achieve the purpose of lowering the stage, so as to achieve tumor resection.For example, the Checkmate 816 study, presented at the 2021 Annual meeting of the American Society of Clinical Oncology (ASCO), evaluated the efficacy and safety of neoadjuvant therapy for patients with non-small cell lung cancer (STAGE IB-IIIA) in combination with chemotherapy.Immunotherapy combined with chemotherapy as a neoadjuvant therapy can achieve more effective results.The recurrence of lung cancer is a "nightmare" in the hearts of many patients and their families, and even many people think that once the recurrence of lung cancer means "no medicine can be treated", not far from death.But in fact, even if there is a second recurrence of lung cancer, surgical resection can also be taken to obtain a good prognosis.A patient diagnosed 4 years ago with moderately differentiated squamous cell carcinoma (T2aN0M0, stage ⅰ B) experienced a recurrence of the cancer after left lung resection and chemotherapy.This time many doctors decided there was no chance of surgery.However, he did not give up hope. With the help of Hopu Ark, he found Japanese lung cancer expert Professor Kenji Suzuki, who evaluated the patient's condition and decided there was still a chance of surgery.At present, the patient has completed surgery in Japan to completely remove the lung tumor.In conclusion, even patients with advanced lung cancer still have a chance of clinical cure if reasonable treatment, including surgery, can be taken at the first time of diagnosis by an experienced expert.Kenji Suzuki, director of respiratory Surgery department of Sunheaven Hospital affiliated to Sunheaven University in Japan, is the leading lung cancer treatment expert in Japan. The five-year survival rate of patients treated by him is as high as 95%, and the incidence of complications is about 1/5 of that of major institutions in Europe and America.Suzuki professor is very good at lung cancer surgery, and make full use of the tough operation of skilled technology and is well known in the world, and have 3 b period of 5 years of survival rate is as high as 40% of patients with lung cancer stage 3 b (Japan lung cancer overall 5 year survival rate was 22%), the average intraoperative mortality was 0.3%, the bleeding as low as 3 ml of proud achievement, maintain a higher level in the field of global lung cancer treatment.At the same time, Suzuki kenji has rich experience in minimally invasive surgery for lung cancer - Da Vinci robotic surgery, and is a core member of the world Da Vinci robotic equipment r&d team.Professor Suzuki signed a contract with Hopu Ark as a cooperative expert. Over the years, he has worked with Hopu Ark to provide "good, fast and cost-effective" overseas medical services "patient-centered", helping many domestic patients to get rid of lung cancer.If you or your friends are also suffering from the threat or trouble of lung cancer and want to make a quick appointment with Professor Kenji Suzuki for more effective diagnosis and treatment advice, you can contact xiaobian via private letter.Reference:[1] the world health organization's international agency for research on cancer (iarc) https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/ http://www.zengankyo.ncc.go.jp/e [2] Japan's national cancer research centertc/seizonritsu/seizonritsu2012.html#10[3] Yun, J.K., Lee, G.D., Choi, S. et al. Video-assisted thoracoscopic lobectomy is feasible for selected patients with clinical N2 non-small cell lung Cancer. Sci Rep 10, 15217 (2020). https://doi.org/10.1038/s41598-020-72272-4 [4] Soliman, b. g., Nguyen, d. t. Chan,E. Y., Chihara, R. K., Meisenbach, L. M., Graviss, E. A., & Kim, M. P. (2020). Impact of da Vinci Xi robot in pulmonary resection. Journal of thoracic disease, 12(7), 3561-3572. [5] https://doi.org/10.21037/jtd-20-720 juntendo university school of medicine affiliated hospital juntendo https://www.juntendo.ac.jp/hospital/ [6] the Quality of Life in Octogenarians after Lung Resection Compared to Younger Patientshttps://www.clinical-lung-cancer.com/article/S1525-7304(21)00141-8/abstract[7] Wakelee et, al. ASCO 2021, Abstract 8500.